195 related articles for article (PubMed ID: 25402332)
1. A pilot study on reparixin, a CXCR1/2 antagonist, to assess safety and efficacy in attenuating ischaemia-reperfusion injury and inflammation after on-pump coronary artery bypass graft surgery.
Opfermann P; Derhaschnig U; Felli A; Wenisch J; Santer D; Zuckermann A; Dworschak M; Jilma B; Steinlechner B
Clin Exp Immunol; 2015 Apr; 180(1):131-42. PubMed ID: 25402332
[TBL] [Abstract][Full Text] [Related]
2. Blockade of CXCR1/2 chemokine receptors protects against brain damage in ischemic stroke in mice.
Sousa LF; Coelho FM; Rodrigues DH; Campos AC; Barcelos Lda S; Teixeira MM; Rachid MA; Teixeira AL
Clinics (Sao Paulo); 2013; 68(3):391-4. PubMed ID: 23644861
[TBL] [Abstract][Full Text] [Related]
3. Targeting CXCR1/2 Does Not Improve Insulin Secretion After Pancreatic Islet Transplantation: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial in Type 1 Diabetes.
Maffi P; Lundgren T; Tufveson G; Rafael E; Shaw JAM; Liew A; Saudek F; Witkowski P; Golab K; Bertuzzi F; Gustafsson B; Daffonchio L; Ruffini PA; Piemonti L;
Diabetes Care; 2020 Apr; 43(4):710-718. PubMed ID: 32019854
[TBL] [Abstract][Full Text] [Related]
4. A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer.
Goldstein LJ; Perez RP; Yardley D; Han LK; Reuben JM; Gao H; McCanna S; Butler B; Ruffini PA; Liu Y; Rosato RR; Chang JC
Breast Cancer Res; 2020 Jan; 22(1):4. PubMed ID: 31924241
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of CXCR1 and CXCR2 chemokine receptors attenuates acute inflammation, preserves gray matter and diminishes autonomic dysreflexia after spinal cord injury.
Marsh DR; Flemming JM
Spinal Cord; 2011 Mar; 49(3):337-44. PubMed ID: 20877331
[TBL] [Abstract][Full Text] [Related]
6. Reduction of NETosis by targeting CXCR1/2 reduces thrombosis, lung injury, and mortality in experimental human and murine sepsis.
Alsabani M; Abrams ST; Cheng Z; Morton B; Lane S; Alosaimi S; Yu W; Wang G; Toh CH
Br J Anaesth; 2022 Feb; 128(2):283-293. PubMed ID: 34893315
[TBL] [Abstract][Full Text] [Related]
7. Targeting CXCR1/2 in the first multicenter, double-blinded, randomized trial in autologous islet transplant recipients.
Witkowski P; Wijkstrom M; Bachul PJ; Morgan KA; Levy M; Onaca N; Chaidarun SS; Gardner T; Shapiro AMJ; Posselt A; Ahmad SA; Daffonchio L; Ruffini PA; Bellin MD
Am J Transplant; 2021 Nov; 21(11):3714-3724. PubMed ID: 34033222
[TBL] [Abstract][Full Text] [Related]
8. Reparixin, a specific interleukin-8 inhibitor, has no effects on inflammation during endotoxemia.
Leitner JM; Mayr FB; Firbas C; Spiel AO; Steinlechner B; Novellini R; Jilma B
Int J Immunopathol Pharmacol; 2007; 20(1):25-36. PubMed ID: 17346425
[TBL] [Abstract][Full Text] [Related]
9. Reparixin, an inhibitor of CXCR1 and CXCR2 receptor activation, attenuates blood pressure and hypertension-related mediators expression in spontaneously hypertensive rats.
Kim HY; Choi JH; Kang YJ; Park SY; Choi HC; Kim HS
Biol Pharm Bull; 2011; 34(1):120-7. PubMed ID: 21212529
[TBL] [Abstract][Full Text] [Related]
10. The effect of remote ischaemic preconditioning on myocardial injury in patients undergoing off-pump coronary artery bypass graft surgery.
Hong DM; Mint JJ; Kim JH; Sohn IS; Lim TW; Lim YJ; Bahk JH; Jeon Y
Anaesth Intensive Care; 2010 Sep; 38(5):924-9. PubMed ID: 20865880
[TBL] [Abstract][Full Text] [Related]
11. Doxycycline reduces cardiac matrix metalloproteinase-2 activity but does not ameliorate myocardial dysfunction during reperfusion in coronary artery bypass patients undergoing cardiopulmonary bypass.
Schulze CJ; Castro MM; Kandasamy AD; Cena J; Bryden C; Wang SH; Koshal A; Tsuyuki RT; Finegan BA; Schulz R
Crit Care Med; 2013 Nov; 41(11):2512-20. PubMed ID: 23928836
[TBL] [Abstract][Full Text] [Related]
12. Synergy of isoflurane preconditioning and propofol postconditioning reduces myocardial reperfusion injury in patients.
Huang Z; Zhong X; Irwin MG; Ji S; Wong GT; Liu Y; Xia ZY; Finegan BA; Xia Z
Clin Sci (Lond); 2011 Jul; 121(2):57-69. PubMed ID: 21291422
[TBL] [Abstract][Full Text] [Related]
13. Development of a systemically-active dual CXCR1/CXCR2 allosteric inhibitor and its efficacy in a model of transient cerebral ischemia in the rat.
Garau A; Bertini R; Mosca M; Bizzarri C; Anacardio R; Triulzi S; Allegretti M; Ghezzi P; Villa P
Eur Cytokine Netw; 2006 Mar; 17(1):35-41. PubMed ID: 16613761
[TBL] [Abstract][Full Text] [Related]
14. Aortic and mitral valve surgery on the beating heart is lowering cardiopulmonary bypass and aortic cross clamp time.
Gersak B; Sutlic Z
Heart Surg Forum; 2002; 5(2):182-6. PubMed ID: 12125670
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of pyridoxal 5'-phosphate (MC-1) in high-risk patients undergoing coronary artery bypass graft surgery: the MEND-CABG II randomized clinical trial.
; Alexander JH; Emery RW; Carrier M; Ellis SJ; Mehta RH; Hasselblad V; Menasche P; Khalil A; Cote R; Bennett-Guerrero E; Mack MJ; Schuler G; Harrington RA; Tardif JC
JAMA; 2008 Apr; 299(15):1777-87. PubMed ID: 18381567
[TBL] [Abstract][Full Text] [Related]
16. Effects of urinary protease inhibitor on inflammatory response during on-pump coronary revascularisation. Effect of ulinastatin on inflammatory response.
Bingyang J; Jinping L; Mingzheng L; Guyan W; Zhengyi F
J Cardiovasc Surg (Torino); 2007 Aug; 48(4):497-503. PubMed ID: 17653011
[TBL] [Abstract][Full Text] [Related]
17. Impact of intravenous exenatide infusion for perioperative blood glucose control on myocardial ischemia-reperfusion injuries after coronary artery bypass graft surgery: sub study of the phase II/III ExSTRESS randomized trial.
Besch G; Perrotti A; Salomon du Mont L; Puyraveau M; Ben-Said X; Baltres M; Barrucand B; Flicoteaux G; Vettoretti L; Samain E; Chocron S; Pili-Floury S
Cardiovasc Diabetol; 2018 Nov; 17(1):140. PubMed ID: 30384842
[TBL] [Abstract][Full Text] [Related]
18. Preoperative oral thyroid hormones to prevent euthyroid sick syndrome and attenuate myocardial ischemia-reperfusion injury after cardiac surgery with cardiopulmonary bypass in children: A randomized, double-blind, placebo-controlled trial.
Zhang JQ; Yang QY; Xue FS; Zhang W; Yang GZ; Liao X; Meng FM
Medicine (Baltimore); 2018 Sep; 97(36):e12100. PubMed ID: 30200092
[TBL] [Abstract][Full Text] [Related]
19. Phase Ib Pilot Study to Evaluate Reparixin in Combination with Weekly Paclitaxel in Patients with HER-2-Negative Metastatic Breast Cancer.
Schott AF; Goldstein LJ; Cristofanilli M; Ruffini PA; McCanna S; Reuben JM; Perez RP; Kato G; Wicha M
Clin Cancer Res; 2017 Sep; 23(18):5358-5365. PubMed ID: 28539464
[No Abstract] [Full Text] [Related]
20. Evaluation of leukocyte-depleted terminal blood cardioplegic solution in patients undergoing elective and emergency coronary artery bypass grafting.
Sawa Y; Matsuda H; Shimazaki Y; Kaneko M; Nishimura M; Amemiya A; Sakai K; Nakano S
J Thorac Cardiovasc Surg; 1994 Dec; 108(6):1125-31. PubMed ID: 7983882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
